Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart failure patients may get a new diuretic boost

NCT ID NCT06285760

Knowledge-focused Sponsor: Puerta de Hierro University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether adding a drug called acetazolamide (used for glaucoma) to standard heart failure treatment helps people with acute heart failure pass more urine and salt. Researchers will measure urine output over 24 hours in 64 hospitalized adults who still have fluid buildup despite taking furosemide and SGLT2 inhibitors. The goal is to see if this combination works better at reducing congestion.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 64 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2024

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients admitted for heart failure with persistent findings of residual congestion who meet the inclusion criteria and none of the exclusion criteria.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients admitted for acute heart failure and ≥ 1 clinical sign of volume overload (edema, ascites, or pleural effusion). * NTproBNP levels \>1000 pg/mL or BNP \>250 ng/mL on admission. * Under treatment with furosemide and iSGLT2 according to European guidelines and indication of association of another diuretic due to residual congestion data defined by ADVOR SCORE\>1. Exclusion Criteria: * Systolic blood pressure \<90 mmHg or mean arterial pressure \< 65 mmHg. * Maintenance treatment with acetazolamide/ Treatment with acetazolamide in the month prior to inclusion in the study. * Anticipated need for intravenous inotropes, vasopressors or nitroprusside during the study. * Contraindication to ISGLT2. * Type 1 diabetes mellitus * GFR \< 20 ml/min/m2 or renal replacement therapy/ultrafiltration at any time prior to the study. * Anticipated exposure to nephrotoxic agents, such as iodinated contrast during admission. * Concurrent diagnosis of acute coronary syndrome. * History of congenital heart disease requiring surgical correction. * History of cardiac transplantation and/or ventricular assist device. * Pregnant or breastfeeding patients. * Inability to adequately collect diuresis. * Serum potassium less than 3.5 mEq/L. * Venous pH \<7.30 * Severe aortic stenosis or obstructive hypertrophic cardiomyopathy. * Sulfonamide allergy, liver cirrhosis, renal lithiasis.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart failure Persistent congestion

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Julia González González

    RECRUITING

    Madrid, 28222, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.